HRP20120535T1 - Dihidroksi izopropil fenil morfolin ilmetil fenil izoksazol karboksilna kiselina etilamid mesilat njegovi hidrati i polimorfi te formulacije koje sadrže te oblike - Google Patents

Dihidroksi izopropil fenil morfolin ilmetil fenil izoksazol karboksilna kiselina etilamid mesilat njegovi hidrati i polimorfi te formulacije koje sadrže te oblike Download PDF

Info

Publication number
HRP20120535T1
HRP20120535T1 HRP20120535AT HRP20120535T HRP20120535T1 HR P20120535 T1 HRP20120535 T1 HR P20120535T1 HR P20120535A T HRP20120535A T HR P20120535AT HR P20120535 T HRP20120535 T HR P20120535T HR P20120535 T1 HRP20120535 T1 HR P20120535T1
Authority
HR
Croatia
Prior art keywords
phenyl
morpholin
ylmethyl
dihydroxy
carboxylic acid
Prior art date
Application number
HRP20120535AT
Other languages
English (en)
Inventor
Martin@James@Drysdale
Brian@William@Dymock
Christoph@Krell
Michael@Mutz
Holger@Petersen
Weijia@Zheng
Original Assignee
Novartis@Ag
Vernalis@@R@D@@Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38134307&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120535(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis@Ag, Vernalis@@R@D@@Ltd filed Critical Novartis@Ag
Publication of HRP20120535T1 publication Critical patent/HRP20120535T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Spoj naznačen time da je dihidroksi izopropil fenil morfolin ilmetil fenil izoksazol karboksilna kiselina etilamid mesilat Patent sadrži još patentnih zahtjeva

Claims (9)

1. Spoj, naznačen time, da je 5-(2,4-dihidroksi-5-izopropil-fenil)-4-(4-morfolin-4-ilmetil-fenil)-izoksazol-3-karboksilna kiselina etilamid mesilat.
2. Kristalni oblik, naznačen time, da je od spoja 5-(2,4-dihidroksi-5-izopropil-fenil)-4-(4-morfolin-4-ilmetil-fenil)-izoksazol-3-karboksilna kiselina etilamid mesilat.
3. Kristalni oblik prema zahtjevu 2, naznačen time, da je 5-(2,4-dihidroksi-5-izopropil-fenil)-4-(4-morfolin-4-ilmetil-fenil)-izoksazol-3-karboksilna kiselina etilamid mesilat anhidrat.
4. Kristalni oblik I, naznačen time, da je od spoja 5-(2,4-dihidroksi-5-izopropil-fenil)-4-(4-morfolin-4-ilmetil-fenil)-izoksazol-3-karboksilna kiselina etilamid mesilat anhidrat, s uzorkom difrakcije X-zraka izraženim u razmacima od 2-teta vrijednosti, koji sadrži vršne vrijednosti na 8,0; 11,9; 13,9; 14,2; 16,7; 18,5; 19,4; 22,7; 23,3 ± 0,2 stupnj(ev)a.
5. Kristalni oblik prema zahtjevu 2, naznačen time, da je to hidrat od spoja 5-(2,4-dihidroksi-5-izopropil-fenil)-4-(4-morfolin-4-ilmetil-fenil)-izoksazol-3-karboksilna kiselina etilamid mesilat.
6. Hidratni oblik HA, naznačen time, da je od spoja 5-(2,4-dihidroksi-5-izopropil-fenil)-4-(4-morfolin-4-ilmetil-fenil)-izoksazol-3-karboksilna kiselina etilamid mesilat, koji pokazuje dijagram difrakcije X-zraka izražen u razmaku od 2-teta vrijednosti, koji sadrži vršne vrijednosti na 11,0; 11,6; 14,1; 18,1; 20,1; 20,5; 21,1; 21,7; 21,9; 25,8 ± 0,2 stupnj(ev)a.
7. Hidratni oblik HB, naznačen time, da je od spoja 5-(2,4-dihidroksi-5-izopropil-fenil)-4-(4-morfolin-4-ilmetil-fenil)-izoksazol-3-karboksilna kiselina etilamid mesilat, koji pokazuje dijagram difrakcije X-zraka izražen u razdoblju od 2-teta vrijednosti, koji sadrži vršne vrijednosti na 6,2; 10,1; 12,6; 14,5; 18,0; 18,5; 19,0; 20,4; 20,9; 21,8; 22,2; 25,4 ± 0,2 stupnj(ev)a.
8. Formulacija, naznačena time, da obuhvaća 5-(2,4-dihidroksi-5-izopropil-fenil)-4-(4-morfolin-4-ilmetil-fenil)-izoksazol-3-karboksilna kiselina etilamid mesilat, gdje se radi o vodenoj otopini koja sadrži 5-(2,4-dihidroksi-5-izopropil-fenil)-4-(4-morfolin-4-ilmetil-fenil)-izoksazol-3-karboksilna kiselina etilamid mesilata slobodnog od bilo koje ostale soli, s pH vrijednosti između 3,2 i 5,2.
9. Formulacija, naznačena time, da se sastoji od izotonične vodene otopine mesilatne soli od spoja 5-(2,4-dihidroksi-5-izopropil-fenil)-4-(4-morfolin-4-ilmetil-fenil)-izoksazol-3-karboksilna kiselina etilamid i 5 masenih% glukoze ili manitola.
HRP20120535AT 2007-03-01 2012-06-28 Dihidroksi izopropil fenil morfolin ilmetil fenil izoksazol karboksilna kiselina etilamid mesilat njegovi hidrati i polimorfi te formulacije koje sadrže te oblike HRP20120535T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07103346 2007-03-01
PCT/EP2008/052443 WO2008104595A1 (en) 2007-03-01 2008-02-28 Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms

Publications (1)

Publication Number Publication Date
HRP20120535T1 true HRP20120535T1 (hr) 2012-07-31

Family

ID=38134307

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120535AT HRP20120535T1 (hr) 2007-03-01 2012-06-28 Dihidroksi izopropil fenil morfolin ilmetil fenil izoksazol karboksilna kiselina etilamid mesilat njegovi hidrati i polimorfi te formulacije koje sadrže te oblike

Country Status (41)

Country Link
US (3) US8163747B2 (hr)
EP (2) EP2131845B1 (hr)
JP (1) JP2010520176A (hr)
KR (1) KR20090122218A (hr)
CN (2) CN102302500A (hr)
AR (1) AR065519A1 (hr)
AT (1) ATE552836T1 (hr)
AU (1) AU2008220800B2 (hr)
BR (1) BRPI0807992A2 (hr)
CA (1) CA2678043A1 (hr)
CL (1) CL2008000618A1 (hr)
CO (1) CO6210828A2 (hr)
CR (1) CR10989A (hr)
CY (1) CY1113805T1 (hr)
DK (1) DK2131845T3 (hr)
DO (1) DOP2009000209A (hr)
EA (1) EA017075B1 (hr)
EC (1) ECSP099602A (hr)
ES (1) ES2384906T3 (hr)
GE (1) GEP20115309B (hr)
GT (1) GT200900236A (hr)
HK (1) HK1139073A1 (hr)
HR (1) HRP20120535T1 (hr)
IL (1) IL200401A0 (hr)
MA (1) MA31204B1 (hr)
MX (1) MX2009009233A (hr)
NI (1) NI200900161A (hr)
NZ (1) NZ578854A (hr)
PA (1) PA8771101A1 (hr)
PE (1) PE20090166A1 (hr)
PL (1) PL2131845T3 (hr)
PT (1) PT2131845E (hr)
RS (1) RS52351B (hr)
SI (1) SI2131845T1 (hr)
SM (1) SMAP200900080A (hr)
TN (1) TN2009000357A1 (hr)
TW (1) TW200844102A (hr)
UA (1) UA101950C2 (hr)
UY (1) UY30943A1 (hr)
WO (1) WO2008104595A1 (hr)
ZA (1) ZA200905417B (hr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200922595A (en) * 2007-10-12 2009-06-01 Novartis Ag Organic compounds
TWI450898B (zh) * 2008-07-04 2014-09-01 Sigma Tau Res Switzerland Sa 具有抗腫瘤活性之芳基異唑化合物
US8309578B2 (en) 2008-11-25 2012-11-13 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
ES2578513T3 (es) * 2010-01-21 2016-07-27 Aprea Ab Solución acuosa que comprende 3-quinuclidinona para el tratamiento de enfermedades hiperproliferativas, autoinmunes y cardiacas
WO2011102660A2 (en) * 2010-02-17 2011-08-25 Ildong Pharm Co., Ltd. A novel 5-membered heterocycle derivatives and manufacturing process thereof
KR20120031854A (ko) 2010-09-27 2012-04-04 한국전자통신연구원 시간 및 주파수 특징을 이용하는 음악 음원 분리 장치 및 방법
WO2013015661A2 (en) * 2011-07-28 2013-01-31 Ildong Pharm Co.,Ltd. Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1771235B (zh) * 2003-02-11 2010-04-28 弗奈利斯(剑桥)有限公司 异噁唑化合物
US20060070405A1 (en) * 2004-10-06 2006-04-06 Anheuser-Busch, Inc. Method for the production of amber glass with reduced sulfur-containing emissions
WO2008100985A2 (en) 2007-02-15 2008-08-21 Novartis Ag Combination of lbh589 with other therapeutic agents for treating cancer
WO2010069458A1 (de) 2008-12-17 2010-06-24 Merck Patent Gmbh Hexahalochromat(lll)-komplexe

Also Published As

Publication number Publication date
TN2009000357A1 (en) 2010-12-31
SMAP200900080A (it) 2010-01-19
CY1113805T1 (el) 2016-07-27
NI200900161A (es) 2010-07-27
AU2008220800B2 (en) 2012-02-16
US8163747B2 (en) 2012-04-24
CR10989A (es) 2010-03-01
AR065519A1 (es) 2009-06-10
BRPI0807992A2 (pt) 2014-06-17
UY30943A1 (es) 2008-10-31
CN102302500A (zh) 2012-01-04
GT200900236A (es) 2011-09-14
IL200401A0 (en) 2010-04-29
MX2009009233A (es) 2010-06-02
PL2131845T3 (pl) 2012-09-28
ES2384906T3 (es) 2012-07-13
WO2008104595A1 (en) 2008-09-04
ECSP099602A (es) 2009-12-28
US20120172592A1 (en) 2012-07-05
US8487095B2 (en) 2013-07-16
CL2008000618A1 (es) 2008-09-12
EP2131845B1 (en) 2012-04-11
GEP20115309B (en) 2011-10-25
CN101636162A (zh) 2010-01-27
ZA200905417B (en) 2010-05-26
PT2131845E (pt) 2012-07-10
ATE552836T1 (de) 2012-04-15
AU2008220800A1 (en) 2008-09-04
JP2010520176A (ja) 2010-06-10
DK2131845T3 (da) 2012-07-16
EP2545921A3 (en) 2013-04-10
CA2678043A1 (en) 2008-09-04
NZ578854A (en) 2012-03-30
SI2131845T1 (sl) 2013-02-28
UA101950C2 (ru) 2013-05-27
US20100093732A1 (en) 2010-04-15
EA200901141A1 (ru) 2010-04-30
MA31204B1 (fr) 2010-02-01
KR20090122218A (ko) 2009-11-26
EP2545921A2 (en) 2013-01-16
EA017075B1 (ru) 2012-09-28
DOP2009000209A (es) 2009-09-15
EP2131845A1 (en) 2009-12-16
RS52351B (en) 2012-12-31
US20130296556A1 (en) 2013-11-07
TW200844102A (en) 2008-11-16
PE20090166A1 (es) 2009-03-14
PA8771101A1 (es) 2009-02-09
CO6210828A2 (es) 2010-10-20
HK1139073A1 (hr) 2010-09-10

Similar Documents

Publication Publication Date Title
HRP20120535T1 (hr) Dihidroksi izopropil fenil morfolin ilmetil fenil izoksazol karboksilna kiselina etilamid mesilat njegovi hidrati i polimorfi te formulacije koje sadrže te oblike
PE20061490A1 (es) Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
WO2010129500A3 (en) Nematocidal sulfonamides
PE20091816A1 (es) Inhibidores de bace
CY1109831T1 (el) Νεα βιομηχανικη μεθοδος συνθεσης τετραεστερων του 5-[δις(καρβοξυμεθυλ)αμινο]-3-καρβοξυμεθυλ-4-κυανο-2-θειοφαινοκαρβοξυλικου οξεος, και εφαρμογη στη συνθεση δισθενων αλατων του ρανελικου οξεος και των ενυδρων αλατων τους
AR081226A1 (es) Polimorfo cristalino de 4-[5-[3-cloro-5-(trifluorometil)fenil]-4,5-dihidro-5-(trifluorometil)-3-isoxazolil]-n-[2-oxo-2-[(2,2,2-trifluoroetil)amino]etil]-1-naftalenocarboxamida
PE20071185A1 (es) Derivados de fenilo como moduladores de ppar
BR122018001898B8 (pt) Composição para controlar pragas invertebradas e composição
PE20090609A1 (es) Compuestos de pirazol para controlar plagas de invertebrados
CO5650228A2 (es) Sales farmaceuticamente utiles de derivados de acido carboxilico
RU2008139904A (ru) Фармацевтическая композиция для наружного применения
JP2005539100A5 (hr)
MX2010007679A (es) Compuestos herbicidas.
PE20121515A1 (es) Acido 2-({3'-cloro-4'-[(2,2-dimetilpirrolidin-1-il)carbonil]-5-fluorobifenil-2-il}oxi)propanoico y sus sales como moduladores del receptor crth2
NZ592224A (en) Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition
NI200500065A (es) Nuevos procesos para la sintesis industrial del diester metilico del 5-amino-3-carboximetil-4-ciano-2-acido tiofenecarboxilico y aplicacion a la sintesis de sales bivalentes de acido ranelico y de sus hidratos.
ATE492159T1 (de) Niedrigschmelzende biocidformulierung
ES2572136T3 (es) Proceso para fabricar un material biomédico basado en fosfato de calcio
AR073201A1 (es) Compuestos de amida y su uso.
PE20081200A1 (es) Sal de potasio cristalina de analogos de lipoxina a4
BRPI0519600A2 (pt) processos para produzir 4- aminoquinazolinas
AR075308A1 (es) Composicion para controlar fitoenfermedades y metodo para controlar fitoenfermedades
NO20083588L (no) Improved crystalline material
PE20090602A1 (es) Nuevos compuestos
MY133333A (en) New salts